Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | IAPP | P10997 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43506 | 1.00 | PYGL (0.45) | PYGLPTGS2PTGS1DHODHPELI1 | |
| SCHEMBL4212119 | 0.85 | AKR1C3 (0.52) | PYGLPTGS2DHODHESR1BACE1 | |
| SCHEMBL28590185 | 0.81 | TTR (0.56) | PYGLDHODHNOS3NOS1NOS2 | |
| SCHEMBL5380481 | 0.81 | PYGL (0.60) | PYGLPTGS2 | |
| SCHEMBL5380483 | 0.81 | PYGL (0.60) | PYGLPTGS2 | |
| Ether SCHEMBL5385034 | 0.80 | PYGL (0.53) | PYGLPTGS2DHODHNOS3NOS1 | |
| Ether SCHEMBL5385030 | 0.80 | PYGL (0.53) | PYGLPTGS2DHODHNOS3NOS1 | |
| SCHEMBL7612805 | 0.80 | PELI1 (0.44) | PYGLPTGS2PELI1BACE1 | |
| SCHEMBL7612808 | 0.80 | PELI1 (0.44) | PYGLPTGS2PELI1BACE1 | |
| Hydrochloric Acid SCHEMBL5886161 | 0.80 | PYGL (0.58) | PYGLPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011157670-A2 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157670-A2 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313196-A1 | NOVEL PROCESS | CYP3A5, CYP3A4, GBA1 | PYGL 1590/4885PTGS2 1138/4885PTGS1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.